Focus: Orphalan is a French biotech company focused on rare disease treatment, with a commercial footprint built on CUVRIOR (trientine tetrahydrochloride) for Wilson's disease. The company operates as a public entity with a highly specialized, orphan disease-centric model.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
Orphalan offers rare-disease domain expertise and revenue stability, but single-product dependence and anemic hiring suggest limited career mobility and growth ceiling.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue driver representing 100% of company income; patent protection extends to 2039, ensuring long-term commercial runway.
Help build intelligence for Orphalan
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Orphalan's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease: Monitoring chelation treatment in Wilson disease.
Authors' Reply to Purchase's Comment on "Trientine Tetrahydrochloride, from Bench to Beside: A Narrative Review".
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo